drugset / Trial / NCT02492490

Effect of SVF Derived MSC in DCD Renal Transplantation

NCT02492490

Phase 1/2 Unknown 120 enrolled Fuzhou General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this trial is to determine if autologous Stromal Vascular Fraction (SVF) derived Mesenchymal Stem Cell (MSC) infusion during and after kidney transplantation from Donation after Citizen Death (DCD) can effectively reduce the need for post transplant immunosuppressant and elevate GFR of allograft. The investigators will infuse autologous SVF derived MSC to the recipients during and after operation to assess the effect of SVF derived MSC and closely monitor renal function, dosage of immunosuppressant, acute rejection, and graft survival. 120 patients eligible for the study as described below will be enrolled, with 60 patients in intervention group and 60 in control group.

Timeline

Start
2014-12
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Basiliximab Monoclonal antibody

Indications